Literature DB >> 18580956

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison.

M Mohty, H de Lavallade, J El-Cheikh, P Ladaique, C Faucher, S Fürst, N Vey, D Coso, A-M Stoppa, J-A Gastaut, C Chabannon, D Blaise.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18580956     DOI： 10.1038/leu.2008.164

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Re: Allogeneic stem cell transplantation in acute myeloid leukemia--establishment of indications on the basis of individual risk stratification. Statement was not sufficiently supported.

Authors:  Annegret Herrmann-Frank; Klaus Koch; Stefan Lange; Peter T Sawicki
Journal:  Dtsch Arztebl Int       Date:  2009-02-06       Impact factor: 5.594

2.  Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

Authors:  B K Hamilton; L Rybicki; J Dabney; L McLellan; H Haddad; L Foster; D Abounader; M Kalaycio; R Sobecks; R Dean; H Duong; B T Hill; B J Bolwell; E A Copelan
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

3.  To RIC or not to RIC: that is the question.

Authors:  M Mohty; F Malard
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

4.  Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

Authors:  Betul Oran; John E Wagner; Todd E DeFor; Daniel J Weisdorf; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

5.  Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype.

Authors:  Philipp G Hemmati; Theis H Terwey; Gero Massenkeil; Philipp le Coutre; Lam G Vuong; Stefan Neuburger; Bernd Dörken; Renate Arnold
Journal:  Int J Hematol       Date:  2010-02-25       Impact factor: 2.490

6.  A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.

Authors:  N H Russell; L Kjeldsen; C Craddock; A Pagliuca; J A Yin; R E Clark; A Howman; R K Hills; A K Burnett
Journal:  Leukemia       Date:  2014-11-07       Impact factor: 11.528

7.  Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Authors:  Gheath Alatrash; Marcos de Lima; Nelson Hamerschlak; Matteo Pelosini; Xuemei Wang; Lianchun Xiao; Fabio Kerbauy; Alexandre Chiattone; Gabriela Rondon; Muzaffar H Qazilbash; Sergio A Giralt; Leandro de Padua Silva; Chitra Hosing; Partow Kebriaei; Weiqing Zhang; Yago Nieto; Rima M Saliba; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-18       Impact factor: 5.742

8.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

9.  Challenges in treating older patients with acute myeloid leukemia.

Authors:  Lagadinou D Eleni; Zoumbos C Nicholas; Spyridonidis Alexandros
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

Review 10.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.

Authors:  Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele
Journal:  Nat Rev Clin Oncol       Date:  2012-09-04       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.